Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Villya Pharmaceuticals acquires Hythlayn's IP

PRIVATEAug 12, 2026about 3 hours ago

Acquiring Company

Villya Pharmaceuticals

Acquired Company

Hythlayn

MelbourneBiotechnologyHealth CarePharmaceuticalManufacturing

Description

Villya Pharmaceuticals has entered the hemp-derived THC beverage market by acquiring the cannabinoid intellectual property of Hythlayn Inc. This acquisition enhances Villya's capabilities in developing innovative solutions for water-based beverages. Villya aims to license the technology to a major global beverage partner, without intending to manufacture beverages itself. This strategic move coincides with an upcoming regulatory shift in the U.S. hemp-derived cannabinoid industry.

Company Information

Company

Villya Pharmaceuticals

Location

Melbourne, Florida, United States

About

Villya Pharmaceuticals, located in Melbourne, FL, focuses on developing innovative drug delivery systems and new therapeutic solutions aimed at improving patient outcomes across various medical fields. Led by CEO William Miller, Villya is dedicated to enhancing lives through scientific innovation, right here in the USA.

Don't miss Villya Pharmaceuticals's next move

Get an email the moment Villya Pharmaceuticals makes an acquisition, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Villya Pharmaceuticals's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Hythlayn?

Hythlayn was acquired by Villya Pharmaceuticals, based in Melbourne. The deal was reported on August 12, 2026. Villya Pharmaceuticals, located in Melbourne, FL, focuses on developing innovative drug delivery systems and new therapeutic solutions aimed at improving patient outcomes across various medical fields. Villya Pharmaceuticals is privately held and operates in Biotechnology.

When did Villya Pharmaceuticals acquire Hythlayn?

Villya Pharmaceuticals's acquisition of Hythlayn was reported on August 12, 2026. Villya Pharmaceuticals has entered the hemp-derived THC beverage market by acquiring the cannabinoid intellectual property of Hythlayn Inc. This acquisition enhances Villya's capabilities in developing innovative solutions for water-based beverages. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Hythlayn do?

Hythlayn Inc. specializes in cannabinoid intellectual property and technology. The company has developed innovative methods for improving cannabinoid solubility. Hythlayn holds several patents aimed at enhancing the beverage industry. It is privately held, operating in Manufacturing.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.